Keypoints {#s1}
=========

1.  \- MHC class II deficiency is a form of severe combined immunodeficiency---urgent referral should be made once the diagnosis is suspected.

2.  \- Severe and chronic viral infections are the hallmarks of the disease.

3.  \- The most prominent immunologic features are the absence or very low HLA-DR expression on lymphocytes, with reduced CD4+ T-lymphocyte counts leading to an inverted CD4/CD8 ratio.

4.  \- Early diagnosis of MHC class II deficiency is important to enable prompt referral to a specialized center for hematopoietic cell transplantation before occurrence of end organ damage secondary to recurrent infection.

Introduction {#s2}
============

Major histocompatibility complex (MHC) class II deficiency, also known as bare lymphocyte syndrome type II, is a rare autosomal recessive combined immunodeficiency and was first described in 1980s ([@B1]). MHC class II molecules are pivotal for the adaptive immune system and guide the development and function of CD4+ T-lymphocytes. The immunologic hallmark of the disease is the absence of constitutive and inducible expression of MHC class II molecules on all cell types which leads to impaired antigen presentation by HLA-DR, HLA-DQ, and HLA-DP molecules on antigen presenting cells (APC) ([@B2]). Besides affecting marrow-derived cells, the lack of MHC class II expression on thymic epithelium also leads to delayed and incomplete maturation of CD4+ T-lymphocytes. MHC class II-mediated peptide presentation is essential for positive and negative selection of the CD4+ T-lymphocyte population in thymus, and for the homeostasis of the mature CD4+ T-lymphocyte population in the periphery. Overall, MHC class II deficiency leads to combined immunodeficiency with defective CD4+ T-lymphocyte maturation and activation and a lack of T helper lymphocyte-dependent antibody production by B-lymphocytes, resulting in significant susceptibility to severe infections and frequently death in early childhood ([@B3]). The reported incidence of MHC class II deficiency ranges from 5% of SCID in Canada to 20--30% of SCID in Kuwait and in North Africans Countries ([@B4], [@B5]).

MHC Class II Deficiency and Genetics {#s3}
====================================

The MHC class II genes are located on chromosome 6 and transcription is tightly regulated according to a strict-cell-type-specific and quantitatively modulated pattern. Their expression is largely restricted to thymic epithelial cells and APC that are dendritic cells, macrophages and B-lymphocytes. In MHC class II deficiency, the MHC locus itself is intact in patients and it is a monogenic disease caused by mutations in the genes encoding for four regulatory factors controlling transcription of MHC class II genes. These regulatory factors are CIITA (class II transactivator), RFX5 (regulatory factor 5), RFXAP (RFX-associated protein), and RFXANK (RFX-associated ankyrin-containing protein) ([Figure 1](#F1){ref-type="fig"}).

![Molecular defects in patients with MHC class II deficiency. Four different transcription factors on MHC class II promoters have been associated with MHC class II deficiency.](fped-07-00516-g0001){#F1}

*CIITA*, which accounts for 15% of MHC class II deficiency, is an inducible factor that controls the expression of MHC class II gene expression by binding to the RFX complex and triggering transcription. The RFXANK, RFX5, and RFXAP proteins are subunits of the ubiquitously expressed RFX complex, which binds directly to the promoters of all MHC class II genes and together with other pleiotropic factors, forms the MHC class II expression enhanceosome ([@B6]). Over 85% of affected children have mutations in genes encoding for RFX complex and half of the reported cases have *RFXANK* deficiency.

Spectrum of Disease in Children With MHC Class II Deficiency {#s4}
============================================================

Although MHC class II deficiency is not considered a classical severe combined immunodeficiency (SCID) according to the International Union of Immunological Societies (IUIS) classification criteria, patients usually present with a clinical phenotype that is very similar to SCID ([@B7]). Infectious susceptibility is broad toward viruses (e.g., cytomegalovirus, herpes simplex), bacteria (e.g., *Staphylococcus* sp., *Streptococci* sp., *Pseudomonas* sp., *Salmonella* sp.), fungi (e.g., *Candida* sp.), and protozoa (e.g., *Pneumocystis jirovecii)*. These infections affect the gastrointestinal, pulmonary, respiratory tracts, beginning in the first year of life. Severe and chronic viral infections are the hallmarks of the disease and are associated with a poor prognosis. Recurrent bronchopulmonary infections caused by bacteria, viruses and *Pneumocystis jirovecii* are frequently observed. Older children may present with organ impairments such as chronic lung disease, chronic diarrhea with malabsorption and growth faltering. Intestinal and hepatic involvement caused by *Crytosporidium* colonization has been reported in patients with MHC class II deficiency; patients may develop chronic liver disease secondary to *cryptosporidium* infection. The absence of generalized BCGitis in these patients might in part be accounted for by the presence of residual immunity in the form of CD8^+^ T-lymphocytes and natural killer cells. Autoimmune manifestations such as autoimmune cytopenia have been observed in 20% of patients with MHC class II deficiency ([@B8]).

Diagnosis and Immunologic Features of Children With MHC Class II Deficiency {#s5}
===========================================================================

Patients with MHC class II deficiency generally have severe CD4+ T-lymphocytopenia, hypogammaglobulinemia and lack of antigen-specific antibody responses. Proliferations to mitogen are usually conserved while absent to antigen. The hallmark finding on lymphocyte phenotypes is the absence or very low HLA-DR expression on lymphocytes, with decreased CD4+ T-lymphocyte counts leading to an inverted CD4/CD8 ratio ([Figure 2](#F2){ref-type="fig"}). The CD4+ lymphocytopenia reflects the abnormal CD4+ thymocyte development, resulting from defective MHC class II expression in the thymus. CD8+ T-lymphocyte counts may be normal or low. T cell receptor excision circles (TREC) has been reported to be measurable in some affected patients and the diagnosis can be missed in TREC-based newborn screening for severe combined immunodeficiency ([@B9]--[@B11]).

![Flow cytometry of a patient MHC class II deficiency. Pre-transplant **(A)** flow cytometry shows absence HLA-DR and post-transplant **(B)** flow cytometry shows presence of HLA-DR.](fped-07-00516-g0002){#F2}

Approach to Haematopoietic Cell Transplantation in Children With MHC Class II Deficiency {#s6}
========================================================================================

The natural history of non-transplanted patients is dismal with a mean age of death at 4 years of age and the main cause of death is overwhelming viral infection ([@B12]). Very few children reach puberty and survive into adulthood ([@B13]). There are no clear differences in prognosis among patients harboring the four different genetic defects. Currently the only known cure for MHC class II deficiency is allogeneic hematopoietic cell transplantation (HCT). Historically this has only been reluctantly offered due to the high risk of transplant-related morbidity and mortality. Additionally, HCT for MHC class II deficiency is challenging as many children have significant comorbidities at the time of HCT. Transplant strategies to optimize the transplant survival of patients with MHC class II deficiency can be divided into three phrases: (1) pre-transplant phase; (2) transplant phase; and (3) post-transplant phase.

Pre-Transplant Phase {#s7}
====================

As younger age at HSCT has been consistently shown to be associated with improved survival in children with primary immunodeficiency, HCT should be performed as early as possible before the onset of organ damage from multiple infections. Some patients with MHC class II deficiency can be detected used TREC-based newborn screening assays, and the diagnosis confirmed by looking for MHC class II expression ([@B9]--[@B11]). Once the diagnosis of MHC class II deficiency is suspected, a child should be referred promptly to an expert team for evaluation and confirmation of the diagnosis. The transplant process should be initiated and performed as soon as possible. Patients might require treatment of infections, respiratory supports and nutritional rehabilitation to optimize their organ function prior to HCT. A multidisciplinary team with participation of respiratory physicians, gastroenterologists, dietitians, play therapies and other supportive groups are required in all the phases in order to achieve the best outcome possible.

Transplant Phase {#s8}
================

This consists of donor selection, appropriate stem cell source and optimal conditioning regimen. As graft-vs. -host disease confers no benefit to patients with MHC class II deficiency, the best HLA-matched donor is a sibling or matched family donor. If no family donor is found, a search of the national or international unrelated donor registries should be undertaken. Parental haploidentical donors with newer methods of T-lymphocyte depletion have emerged as promising alternative donors while classic haploidentical HSCT with CD34+ selection have shown high rate of non-engraftment in historical series ([@B13]--[@B16]).

The use of myeloablative reduced-toxicity conditioning (RTC) is preferred in children with MHC class II deficiency as many patients have multiple chronic infections and organ damage at the time of HCT. RTC reduces early transplant complications and late effects such as infertility. In addition, full donor chimerism is not mandatory since stable mixed chimerism on lymphoid and myeloid compartments have been reported to achieve long-term cures. Experiences with reduced intensity conditioning (RIC) are limited. Al-Mousa et al. reported 12 patients transplanted mainly with intra-familial geno-identical donor after a RIC (flu-mel and ATG) and reported mixed lymphoid and myeloid chimerism in all patients but sufficient to cure the disease ([@B17]). Outside a geno-identical donor, RIC needs to be used with caution. Based on the current evidence, the European Society for Blood and Marrow Transplant developed a guideline for patients with primary immunodeficiencies (PID) ([@B18]). Bone marrow has been the conventional source of stem cells but peripheral blood stem cells have been increasingly used together with RTC to improve donor chimerism ([@B19]).

Post-Transplant Phase {#s9}
=====================

In this phase, the main tasks are monitoring of donor graft, surveillance of transplant-related complications and rehabilitation of pre-transplant organ damage.

Outcome and Immune Reconstitution After Haematopoietic Cell Transplantation in Children With MHC Class II Deficiency {#s10}
====================================================================================================================

More than 100 transplants have been reported worldwide ([Table 1](#T1){ref-type="table"}) ([@B3], [@B14], [@B15], [@B17], [@B20], [@B21], [@B23]--[@B26]). Patients with MHC class II deficiency are difficult to transplant with increased regimen-related toxicities, serious infections, graft rejection, and GvHD. The conditioning protocols used in these patients were variable and the majority of patients were conditioned with Busulfan-based myeloablative conditioning. In the early reports, the transplant survival was poor compared to those seen in patients with other PIDs, with a survival rate of 50% or less ([@B3], [@B14], [@B21], [@B23], [@B24]). Recently, a better transplant outcome has been reported, the overall survival ranges 66--100% and reduced toxicity conditioning has been increasingly used in these reports. ([@B15], [@B17], [@B26]). A high incidence of acute graft-versus-host disease has been reported in these patients and this can be accounted by lack of *in-vivo* T-lymphocyte depletion with serotherapy. High rate of chronic persistent viral infections before transplantation may also increase the risk of GVHD. Patients undergoing HCT before 2 years of age had better prognosis ([@B14]).

###### 

Outcome of allogeneic hematopoietic cell transplantation for MHC class II deficiency.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **References**               **Year of HCT**   **No. of patients**   **Median age at HCT, months (range)**   **Donor and stem cell source**   **Conditioning regimen**                                                                 **GvHD prophylaxis**                **Stem cell doses**                                             **Grade II-IV aGvHD**        **cGvHD**        **OS (%)**
  ---------------------------- ----------------- --------------------- --------------------------------------- -------------------------------- ---------------------------------------------------------------------------------------- ----------------------------------- --------------------------------------------------------------- ---------------------------- ---------------- --------------------------------
  Elfeky et al. ([@B19])       NA                6                     25 (12--38)                             2 10/10 UCB\                     Flu 150 mg/m^2^\                                                                         CSA+MMF                             Median CD34 2.1 × 10^5^/kg                                      4 (67%)                      2                100
                                                                                                               4 9/10 UCB                       Treo 42 g/m^2^\                                                                                                                                                                                                                            
                                                                                                                                                No serotherapy                                                                                                                                                                                                                             

  Small et al. ([@B15])        1990--2013        16                    12 (6--48)                              10 MMFD\                         [TCD marrow/PBSC]{.ul}\                                                                  CSA + MMF                           NA                                                              4 (25%)                      1 post 2nd HCT   69
                                                                                                               4 MUD\                           Bu 16 mg/kg + Flu + Thiotepa or\                                                                                                                                                                                                           
                                                                                                               2 UCB\                           Bu 16 mg/kg + Thiotepa + Cy\                                                                                                                                                                                                               
                                                                                                               5 marrow\                        Bu 16 mg/kg + Flu + Cy\                                                                                                                                                                                                                    
                                                                                                               2 PBSC\                          Bu 16 m/kg + Cy[Unmodified marrow/PBSC]{.ul}\                                                                                                                                                                                              
                                                                                                               1 TCD marrow\                    Bu + Flu + Cy or\                                                                                                                                                                                                                          
                                                                                                               6 TCD PBSC                       Thiotepa +Cy or\                                                                                                                                                                                                                           
                                                                                                                                                Melphalan + Flu + anti-CD52\                                                                                                                                                                                                               
                                                                                                                                                Flu + Cy, anti-CD45 and anti-CD52 or\                                                                                                                                                                                                      
                                                                                                                                                Low dose Cy + Flu + 200cGy TBI\                                                                                                                                                                                                            
                                                                                                                                                [UCB]{.ul}\                                                                                                                                                                                                                                
                                                                                                                                                Flu + Treo without serotherapy                                                                                                                                                                                                             

  Al-Mousa et al. ([@B17])     1994--2007        30\                   27 (1--120)                             26 MFD marrow\                   Bu 16 mg/kg + Cy 200 mg/kg + VP16 300 mg/m^2^ or\                                        CSA + MTX or CSA or CSA + steroid   Median CD34 8.3 × 10^6^/kg (3--20.7 × 10^6^/kg)                 [MAC]{.ul}\                  3                66
                                                 (3 had second HCT)                                            3 MMFD marrow\                   Bu 16 mg/kg +Cy 200 mg/kg + ATG\                                                                                                                                                             9 grade II-III skin aGvHD\                    
                                                                                                               1 UCB                            Cy 200 mg/kg + TBI or\                                                                                                                                                                       5 grade II-III gut aGvHD\                     
                                                                                                                                                Flu 150 mg/m^2^ + melphalan 140 mg/m^2^ +ATG                                                                                                                                                 1 lung GvHD[RIC]{.ul}\                        
                                                                                                                                                                                                                                                                                                                                             7 grade I-II aGvHD                            

  Siepermann et al. ([@B20])   NA                1                     18                                      7/10 UCB                         Bu 20 mg/kg + Flu 160 mg/m^2^ + Cy 120 mg/kg + ATG                                       CSA                                 TNC 9 × 10^7^/Kg                                                Grade I aGvHD                No               Alive

  Renella et al. ([@B21])      1981--2004        15\                   18 (4--65)                              13 MFD marrow\                   Bu 16--20 mg/kg + Cy 200 mg/kg\                                                          CSA + MTX                           Median TNC: 4.3 × 10^9^/kg (3.3 × 10^8^/kg to 5.5 × 10^9^/kg)   7 (47)                       2                53
                                                 (2 had second HCT)                                            2 MUD marrow\                    + ATG in MUD                                                                                                                                                                                                                               
                                                                                                               All 2 second HCT used MSD                                                                                                                                                                                                                                                   

  Saleem et al. ([@B3])        1991--1999        6\                    6.5 (1--15.6 years)                     5 MFD\                           Bu 16--20 mg/kg + Cy 200 mg/kg ± Alemtuzumab ± ATG ± anti-LFA-1/CD2 or Flu + Melphalan   CSA                                 Median TNC: 5.9 × 10^8^/kg (1--11.510^8^/kg)                    NA                           NA               33
                                                 (2 had second HCT)                                            1 MUD                                                                                                                                                                                                                                                                       

  Godthelp et al. ([@B22])     1993--1995        2                     8, 23                                   2 MFD marrow                     Bu 20 mg/kg + Cy 200 mg/kg                                                               CSA + MTX                           TNC 2.5--4.6 × 10^8^/kg                                         None                         None             Both alive

  Bonduel et al. ([@B23])      1994              1\                    22                                      MMUD TCD marrow                  Bu 20 mg/kg + Cy 200 mg/kg + anti-LFA1 + anti-CD2                                        CSA                                 TNC 0.2 × 10^8^/kg                                              Grade II GvHD                None             Alive after second sibling CBT
                                                 (had 2 HCT)                                                                                                                                                                                                                                                                                                                               

  Klein et al. ([@B12])        1981--1993        19\                   17 (6--117)                             8 MFD marrow\                    [MFD]{.ul}\                                                                              CSA+MTX                             TNC 0.6--6.2 × 10^8^/kg                                         6 had Grade II-IV GvHD       NA               47
                                                 (7 had second HCT)                                            1 MMFD marrow\                   Bu20 mg/kg + Cy 200 mg/kg or Cy 50 mg/kg + ALG or\                                                                                                                                                                                         
                                                                                                               10 HID marrow\                   Cy 50 mg/kg + CCNU 300 mg/m^2^ + procarbazine 280 mg/kg + ALG [MMFD]{.ul}\                                                                                                                                                                 
                                                                                                               All 7 second HCT used HID        Bu 16 mg/kg + Cy 200 mg/kg or\                                                                                                                                                                                                             
                                                                                                                                                Bu 20 mg/kg + Cy 200 mg/kg + anti-LFA-1 antibody or\                                                                                                                                                                                       
                                                                                                                                                Bu 20 mg/kg + Cy 200 mg/kg + anti-LFA-1 antibody + anti-CD2 antibody                                                                                                                                                                       

  Fischer et al. ([@B24])      NA                20                    NA                                      8 MFD marrow\                    Bu 8--20 mg/kg\                                                                          MTX ± CSA                           TNC \<4 × 10^8^/kg                                              NA                           NA               35
                                                                                                               12 MMFD marrow                   Cy 200 ml/kg\                                                                                                                                                                                                                              
                                                                                                                                                ±VP16 900 mg/m^2^                                                                                                                                                                                                                          
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*ALG, antilymphocyte globulin; ATG, Antithymocyte globulin; Bu, Busulfan; Cy, cyclosphosphamide; Flu, Fludarabine; Treo, Treosulfan; VP16, etoposide; CSA, ciclosporin; MMF, mycophenolate mofetil; HCT, hematopoietic cell transplantation; HID, haploidentical donor; MFD, Matched family donor; MMFD, mismatched family donor; MD, matched donor; MMD, mismatched donor; PBSC, peripheral blood stem cell; UCB, unrelated cord blood; TCD, T-cell depletion; aGvHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; OS, overall survival*.

Among HSCT long-term survivors, persistent CD4+ T-lymphocytopenia has been observed in post-HCT patients. This observation can ben explained by impaired thymic maturation resulting from defective MHC class II expression on thymic epithelia. Although the CD4+ T-lymphocyte number is low, transplanted patients show normalization of antigen-specific T-lymphocyte stimulation and antibody production in response to vaccination. Partial engraftment post-HCT has been associated with impaired immune repertoire ([@B22]).

Summary {#s11}
=======

MHC class II deficiency is rare but invariably fatal primary immunodeficiency. Allogenic HCT is the only curative treatment and is considered the treatment of choice. Pre-transplant treatment of infections and optimization of nutritional status and organ function are important to improve transplant survival. Transplant survival has improved with reduced toxicity conditioning regimen, better donor availability, improved supportive care, and more effective anti-microbial therapy. There is a need for a multi-center study to delineate the predictors of outcome of HCT in MHC class II deficiency in the modern era of HCT. Advances in gene therapy may be attractive as a potential therapeutic alternative for children with MHC class II deficiency ([@B27], [@B28]).
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